Table 1.
Baselinea Characteristics of the Study and Comparison Cohorts
| Continuously Enrolled | New Treatment Episodes | |||
|---|---|---|---|---|
| Characteristics | Study Cohort (MI) (N=28,798) | Comparison Cohort (IN) (N=21,769) | Study Cohort (MI) (N=3,671) | Comparison Cohort (IN) (N=2,400) |
| Female (%) | 48.1 | 52.2b | 57.0 | 60.8 |
| Age group (%) | ||||
| ≤ 34 | 12.8 | 13.6 | 17.8 | 17.1 |
| 35–54 | 65.9 | 61.9 | 61.2 | 57.4 |
| 55–64 | 21.3 | 24.5b | 21.0 | 25.5b |
| Race (%) | ||||
| White | 78.3 | 85.2 | 74.2 | 86.9 |
| Black | 19.1 | 13.2 | 22.9 | 11.4 |
| Other | 2.4 | 1.4 | 2.9 | 1.5 |
| Unknown | 0.2 | 0.2b | 0.03 | 0.2b |
| Antianxiety Use (%) | 25.4 | 27.5b | 31.0 | 35.0 |
| Antipsychotic Use (%) | ||||
| Typical | 12.3 | 11.2b | 11.8 | 9.4 |
| Atypical | 22.1 | 23.6b | 21.6 | 21.0 |
| Antimanic Use (%) | 3.7 | 3.4 | 3.3 | 3.0 |
| Antidepressant Use (%) | 35.7 | 39.7b | ||
| SSRI/SNRI Only | 48.8 | 43.7 | ||
| SSRI/SNRI + TCA/Other | 23.0 | 28.8 | NA | NA |
| Tricyclics Only | 12.2 | 10.4 | ||
| Other Only | 14.1 | 14.8 | ||
| Any Other Combination | 1.9 | 2.3b | ||
| % with hospital admission | 18.7 | 22.6b | 28.5 | 30.3 |
a
Baseline period is 2001 for continuously enrolled cohort and 10 month before antidepressant initiation for the newly treated cohort.
b
p<0.001 between two states